Compare Stocks

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
CYDY CytoDyn	$0.15	$0.17	$0.13 ▼ $0.42	$149.77M	0.16	2.77 million shs	806,934 shs
NBSE NeuBase Therapeutics	$0.42	$0.71	$0.39 ▼ $5.40	$1.59M	0.83	211,394 shs	47,877 shs
OASM Oasmia Pharmaceutical AB (publ)	$0.02	$1.46	$0.94 ▼ $5.70	$1.50M	0.96	98,414 shs	N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CYDY CytoDyn	0.00%	-6.62%	-11.38%	-17.55%	-51.71%
NBSE NeuBase Therapeutics	+3.70%	+4.97%	-58.43%	-32.29%	-87.22%
OASM Oasmia Pharmaceutical AB (publ)	0.00%	0.00%	0.00%	0.00%	-60.00%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
CYDY CytoDyn	$270K	554.72	N/A	N/A	($0.12) per share	-1.26
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
OASM Oasmia Pharmaceutical AB (publ)	$220K	6.82	N/A	N/A	$0.63 per share	0.03

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
CYDY CytoDyn	-$79.82M	-$0.05	N/A	∞	N/A	N/A	N/A	-478.47%	N/A
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
OASM Oasmia Pharmaceutical AB (publ)	-$18.95M	N/A	0.00	∞	N/A	-8,633.64%	-43.94%	-28.92%	N/A

Latest CYDY, OASM, AVEO, and NBSE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/15/2024	Q3 2024	CYDY CytoDyn	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
CYDY CytoDyn	N/A	0.08	0.07
NBSE NeuBase Therapeutics	N/A	2.87	2.87
OASM Oasmia Pharmaceutical AB (publ)	N/A	0.80	0.73

Ownership

Institutional Ownership

Company	Institutional Ownership
AVEO AVEO Pharmaceuticals	49.95%
CYDY CytoDyn	5.06%
NBSE NeuBase Therapeutics	12.37%
OASM Oasmia Pharmaceutical AB (publ)	0.11%

Insider Ownership

Company	Insider Ownership
AVEO AVEO Pharmaceuticals	3.29%
CYDY CytoDyn	0.71%
NBSE NeuBase Therapeutics	13.90%
OASM Oasmia Pharmaceutical AB (publ)	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
CYDY CytoDyn	12	992.87 million	985.82 million	Not Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
OASM Oasmia Pharmaceutical AB (publ)	57	74.97 million	N/A	Not Optionable

CYDY, OASM, AVEO, and NBSE Headlines

Source	Headline
	Lipigon Pharmaceuticals AB LPGO morningstar.com - March 23 at 12:53 AM
	LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Resurs Holding AB (publ) (RESURS.ST) finance.yahoo.com - February 8 at 12:32 AM
	QuiaPEG Pharmaceuticals Holding AB QUIA morningstar.com - January 6 at 5:30 PM
	Newbury Pharmaceuticals AB (NEWBRY) investing.com - November 29 at 2:08 AM
	Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme bestmediainfo.com - September 26 at 1:06 AM
	Lipigon Pharmaceuticals AB (LPGO) investing.com - September 14 at 9:09 AM
	Speqta publ AB (SPEQT) investing.com - August 25 at 9:50 PM
	PRXXF Paradox Interactive AB (publ) seekingalpha.com - August 25 at 9:29 AM
	Notice of annual general meeting in Alzinova AB (publ) privataaffarer.se - April 25 at 8:37 AM
	Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ) privataaffarer.se - April 21 at 8:26 PM
	Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2) europapress.es - April 2 at 9:53 AM
	OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M seekingalpha.com - February 26 at 11:56 PM
	US regulators clear way for more monkeypox vaccine shipments starherald.com - July 14 at 11:12 AM
	PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN) avanza.se - March 24 at 6:47 AM
	Oasmia expands R&D ability with planned laboratory upgrade privataaffarer.se - March 17 at 8:40 AM
	Orexo appoints Fredrik Järrsten as new CFO stockhouse.com - March 11 at 3:47 AM
	Notice of extra general meeting in Terranet AB finanznachrichten.de - November 29 at 10:24 AM
	Pet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth \| robust CAGR of 7.7% over the forecast period (2017 – 2025). medgadget.com - September 17 at 2:52 AM
	Veterinary Cancer Therapeutics Market Segmentation, Size Analysis, Key Players Forecast To 2027 openpr.com - July 28 at 7:04 PM
	Fancy Wood Industries PCL (FANCY) investing.com - July 22 at 7:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AVEO Pharmaceuticals

NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

CytoDyn

OTCMKTS:CYDY

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Oasmia Pharmaceutical AB (publ)

NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial